EyePoint (STU:PV3B) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PV3B EyePoint Inc STU:PV3B
41 GF Score
Price €11.30
GF Value €0.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is EyePoint Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:PV3B vs SPTX, CRVS, LXRX: Short Percentage of Float Comparison

For the Biotechnology subindustry, EyePoint's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where EyePoint's Short Percentage of Float falls into.


STU:PV3B
41GF Score
EyePoint Inc STU:PV3B
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (STU:PV3B) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of €11.30 is trading 1612.1% above its estimated GF Value™ of €0.66. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for STU:PV3B:

  • Short Percentage of Float:
  • GF Value™: €0.66 vs. price of €11.30 (1612.1% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the STU:PV3B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges EYPT:USA
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
41GF Score

Get the complete analysis for STU:PV3B

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.30
Price
€0.66
GF Value